A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kit-positive Acute Myeloid Leukemia.

Conference Paper

INTRODUCTION: Adults with acute myeloid leukemia (AML) have a high rate of remission; however, more than 50% relapse. C-kit is expressed in approximately 60% of patients with de novo AML and represents a potential therapeutic target. MATERIALS AND METHODS: Patients with newly diagnosed AML received 12 months of imatinib mesylate as maintenance therapy after the completion of post-remission therapy. The primary objective was to determine whether this approach improved progression-free survival (defined as no relapse and no death) compared with historical controls. RESULTS: The median progression-free survival of patients < 60 years of age was 52.1 months (historical control, 13 months) and for patients ≥ 60 years of age was 10.7 months (historical control, 8 months). The median level of AF1q expression was high (9.59), and 84% of patients had moderate or high levels of drug-resistance factors. CONCLUSIONS: Imatinib maintenance therapy may improve the outcome of newly diagnosed patients with AML who are < 60 years of age.

Full Text

Duke Authors

Cited Authors

  • Advani, AS; Tse, W; Li, H; Jia, X; Elson, P; Cooper, B; Ali-Osman, F; Park, J; Rao, AV; Rizzieri, DA; Wang, ES; Cotta, CV; Kalaycio, M; Sobecks, RM; Rouphail, B; Maciejewski, JP; Fensterl, J; Carew, JS; Foster, B; Rush, ML; Tripp, B; Adams, D; Corrigan, D; Griffiths, EA; Sekeres, MA

Published Date

  • February 2021

Published In

Volume / Issue

  • 21 / 2

Start / End Page

  • 113 - 118

PubMed ID

  • 33422470

Electronic International Standard Serial Number (EISSN)

  • 2152-2669

Digital Object Identifier (DOI)

  • 10.1016/j.clml.2020.11.018

Conference Location

  • United States